Following the above-mentioned trail (NCT02541370), the expression of CD133 on circulating endothelial progenitor cells (EPCs), as actors of angiogenesis and neovascularization in advanced HCC, another trial study was conducted to target CD133 on both of CSCs and EPCs and then analyze the changes in circulating multiple plasma molecules in response to CD133 CAR T cells (NCT02541370). The gene discussed is PROM1; the disease is hepatocellular carcinoma.